Malignome der Weichteile und der Knochen
Reference11 articles.
1. Blay JY, Serrano C, Heinrich MC et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol, 2020 Jul;21(7): 923–934. doi: 10.1016/S1470–2045(20)30168–6. Epub 2020 Jun 5.
2. Demetri GD, von Mehren M, Jones RL et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol, 2016 Mar 10;34(8): 786–793. doi: 10.1200/JCO.2015.62.4734. Epub 2015 Sep 14.
3. Demetri GD, Schöffski P, Grignani G et al. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.J Clin Oncol, 2017 Oct 20;35(30): 3433–3439. doi: 10.1200/JCO.2016.71.6605. Epub 2017 Aug 30.
4. Gronchi A, Palmerini E, Quagliuolo V et al. Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J Clin Oncol, 2020 Jul 1;38(19): 2178–2186. doi: 10.1200/JCO.19.03289. Epub 2020 May 18.
5. Heinrich MC, Jones RL, von Mehren M et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol, 2020 Jul;21(7): 935–946. doi: 10.1016/S1470–2045(20)30269–2.